Acalabrutinib study with best supportive care in participants hospitalized with COVID-19

Trial Identifier: D822FC00005
Sponsor: AcertaPharma
Collaborator:
Astrazeneca
Start Date: September 2020
Primary Completion Date: November 2020
Study Completion Date: November 2020
Condition: COVID-19 Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English version
Portuguese Translation

Trial Locations

Country Location
BR Porto Alegre, BR, 90035-003
BR Ribeirão Preto, BR, 14051-140
BR Sao Paulo, BR, 01323-903
BR Sao Paulo, BR, 01321-001
BR Sao Paulo, BR, 05403-000
US, CA Fullerton, CA, US, 92835
US, MD Baltimore, MD, US, 21287
US, MN Rochester, MN, US, 55902
US, NC CHAPEL HILL, NC, US, 27599-7081
US, PA Philadelphia, PA, US, 19140